Safety of Biologic and Immune-modulating Agents in Breast Surgery Procedures: A Retrospective Cohort Analysis.

Authors

Aneeq S Chaudhry, William Tian, Tarifa H Adam, Daniel A Rabin, Matthew Ramsey, Erin Kelley, Katherine Kozlowski, Marco F Ellis, Robert D Galiano

Published in

Aesthetic surgery journal. Jun 22, 2026. Epub Jun 22, 2026.

Abstract

Biologic and targeted immune-modulating agents are increasingly used to manage autoimmune diseases like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. As more patients receiving these therapies undergo elective breast augmentation and implant-based reconstruction, the effect of biologic exposure on postoperative outcomes remains unclear.
This study evaluated whether preoperative use of biologic or immune-modulating agents is associated with increased complications following reconstructive and aesthetic breast surgery procedures.
A retrospective cohort analysis was performed using the TriNetX database. Patients who underwent breast reconstruction or augmentation were identified by Current Procedural Terminology codes and stratified by preoperative exposure to biologic or immune-modulating agents within six months of surgery. Agents included tumor necrosis factor-α, interleukin, Janus kinase, mammalian target of rapamycin, and calcineurin inhibitors, among others. Propensity score matching (1:1) controlled for demographic and clinical covariates. Postoperative complications were assessed at 30-days, 90-days, and 6-months and included wound dehiscence, infection, seroma or hematoma, implant revision, and hospital readmission.
Among 211,105 patients, 4,024 had biologic exposure and 207,081 were controls. After propensity score matching, 3,980 patients remained in each cohort. Complication rates were comparable between groups at all timepoints (p > 0.05). Biologic exposure was not associated with increased risk of wound, infectious, implant revision, or hospital readmission complications.
Preoperative biologic or immune-modulating therapy was not associated with a significant increase in postoperative surgical complications after breast reconstruction or augmentation procedures. Continuing these therapies in appropriate patients appears safe and may reduce unnecessary treatment interruptions.

PMID:
42324957
Bibliographic data and abstract were imported from PubMed on 22 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.